Objective: To evaluate the impact of health professionals' intervention on adherence to statins, the influence on total cholesterol levels, and lifestyle patterns in patients with hypercholesterolemia and analyze the differences according to the center of recruitment.

Study Setting: Forty-six community pharmacies and 50 primary care centers of Spain.

Study Design: Randomized controlled trial design (n = 746). Patients were assigned into adherent (ADH) or nonadherent group depending on their initial adherence to statins. Nonadherent patients were randomly assigned to intervention (INT) or nonintervention (NOINT) group. Patients enrolled in the INT group received an intervention depending on the cause of nonadherence. Patients in the ADH and NOINT groups received usual care. Intention-to-treat (ITT) analysis was performed with multiple imputation to replace the missing data.

Data Collection: Adherence, total cholesterol levels, and lifestyle behaviors.

Findings: The odds of becoming adherent during the 6 months was higher in the INT group compared to the NOINT group (OR = 1,49; 95% CI: 1.30-1.76; P < 0.001), especially in the community pharmacy group (OR = 2.34; 95% CI: 1.81-3.03; P < 0.001). Adherent patients showed lower values of total cholesterol compared with nonadherent patients at baseline (ADH: 200.3 mg/dL vs NOADH: 216.7 mg/dL; P < 0.001) and at the endpoint (ADH: 197.3 mg/dL vs NOADH: 212.2 mg/dL; P < 0.001). More patients enrolled in the INT group practices exercise at the end of the study (INT: +26.6 percent; P = 0.002), and a greater number of patients followed a diet to treat hypercholesterolemia (+30.2 percent; P < 0.001).

Conclusions: The intervention performed by health professionals, especially by community pharmacists, improved adherence to statins by hypercholesterolemic patients, and this improvement in adherence was accompanied by a reduction in total cholesterol levels and a healthier lifestyle.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6505412PMC
http://dx.doi.org/10.1111/1475-6773.13152DOI Listing

Publication Analysis

Top Keywords

adherence statins
12
randomized controlled
8
controlled trial
8
total cholesterol
8
cholesterol levels
8
levels lifestyle
8
noint group
8
int group
8
patients
5
group
5

Similar Publications

Introduction: Hyperlipidemia is increasingly recognized as a significant global health issue, often associated with conditions such as hypertension, diabetes, and obesity. While statins are frequently prescribed to manage lipid levels, recent studies indicate that reliance solely on statin therapy may present certain disadvantages, including prolonged treatment durations, the potential for drug resistance, and various adverse effects. Research indicates that the combination of ezetimibe and statins demonstrates a favorable therapeutic effect in the management of hyperlipidemia.

View Article and Find Full Text PDF

Group-Based Trajectory Models to Evaluate the Association of Lipid Testing and Statin Adherence.

Drugs Real World Outcomes

December 2024

Department of Practice, Sciences and Health Outcomes Research, University of Maryland School of Pharmacy, 220 Arch Street, Baltimore, MD, 21201, USA.

Background And Objective: Performing lipid testing after statin initiation is recommended to monitor response. Inadequate response may indicate non-adherence, which is associated with an increased risk of cardiovascular events and increased costs. Group-based trajectory modeling is an approach to establish probabilistic developmental trajectories of adherence, differentiating individuals by their distinct longitudinal medication-taking behaviors.

View Article and Find Full Text PDF
Article Synopsis
  • Focal segmental glomerulosclerosis (FSGS) is a rare kidney disease that can lead to serious health issues, including kidney failure, and this study aimed to explore its impact specifically among US veterans.
  • Researchers analyzed data from over 2,500 veterans diagnosed with FSGS from 1999 to 2021, noting high prevalence rates, significant comorbidities like hypertension, and substantial healthcare resource utilization.
  • The findings revealed a high mortality rate (51.5%) and a large number of patients requiring kidney-related interventions, with average yearly healthcare costs of $36,543, highlighting the need for improved treatment options.
View Article and Find Full Text PDF

The American College of Cardiology/American Heart Association introduced the Predicting Risk of Cardiovascular EVENTs (PREVENT™) algorithm to estimate the 10-year risk of developing cardiovascular disease. We aimed to assess the cardiovascular risk (CVR) reclassification among rheumatoid arthritis (RA) patients using traditional CVR algorithms-the 2024 PREVENT™ and the 2013 Atherosclerotic Cardiovascular Disease (ASCVD)-and the presence of carotid plaque (CP). This was a cross-sectional study nested of a RA patients' cohort.

View Article and Find Full Text PDF

Efficacy, benefit and safety of inclisiran.

Clin Investig Arterioscler

December 2024

Unidad de Lípidos y Arteriosclerosis, Departamento de Medicina Interna, Hospital Universitario Reina Sofía, Universidad de Córdoba, IMIBIC, CIBEROBN, Córdoba, España. Electronic address:

Hypercholesterolemia is a causal factor of atherosclerotic cardiovascular disease (ASCVD), which is one of the main causes of morbidity and mortality in Spain. The reduction of LDL cholesterol (LDL-C) decreases the risk of ASCVD and adverse cardiovascular events. Targeted therapy for the proprotein convertase subtilisin/kexin type 9 (PCSK-9) has emerged as a novel tool for the treatment of hyperlipidemia.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!